marketcaparena
Search

    OSUR

    ORASURE TECHNOLOGIES INC

    Company overview

    Market capitalization
    $272.43M
    Employees
    500
    Latest publication
    2026-09-29
    About ORASURE TECHNOLOGIES INC

    OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of urine samples; and HEMAcollect protein blood collection device. In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. It sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, and companion animal, markets. The company was founded in 1987 and is headquartered in Bethlehem, Pennsylvania.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ2 20242024-06-30 · USDQ4 20232023-12-31 · USDQ3 20232023-09-30 · USDQ1 20232023-03-31 · USDQ4 20222022-12-31 · USDQ3 20222022-09-30 · USDQ2 20212021-06-30 · USD
    Total Revenue30,639,000USD54,335,000USD75,881,000USD89,187,000USD154,963,000USD123,078,000USD116,463,000USD57,607,000USD
    Cost Of Revenue17,322,000USD28,757,000USD40,239,000USD44,847,000USD89,148,000USD73,250,000USD69,949,000USD26,934,000USD
    Gross Profit13,317,000USD25,578,000USD35,642,000USD44,340,000USD65,815,000USD49,828,000USD46,514,000USD30,673,000USD
    Research Development9,437,000USD6,121,000USD6,991,000USD8,516,000USD10,560,000USD8,052,000USD10,088,000USD7,682,000USD
    Selling General Administrative14,429,000USD11,845,000USD14,005,000USD10,051,000USD17,711,000USD15,944,000USD15,527,000USD10,993,000USD
    Selling And Marketing Expenses6,604,000USD7,931,000USD6,906,000USD8,736,000USD12,142,000USD11,363,000USD13,474,000USD10,420,000USD
    General And Administrative Expenses14,429,000USD———————
    Total Operating Expenses7,877,000USD25,612,000USD27,902,000USD27,303,000USD40,413,000USD35,359,000USD39,089,000USD29,095,000USD
    Operating Income5,440,000USD-34,000USD7,740,000USD17,037,000USD25,402,000USD14,469,000USD7,425,000USD1,578,000USD
    Total Other Income Expense Net1,377,000USD-200,000USD12,980,000USD-3,531,000USD1,592,000USD1,166,000USD-2,973,000USD668,000USD
    Interest Income1,205,000USD———————
    Income Before Tax6,817,000USD-234,000USD20,720,000USD13,506,000USD26,994,000USD15,635,000USD4,452,000USD2,246,000USD
    Income Tax Expense55,000USD381,000USD647,000USD2,347,000USD-225,000USD-166,000USD-1,143,000USD3,610,000USD
    Equity Method Income Loss-513,000USD———————
    Net Income6,249,000USD-615,000USD20,073,000USD11,159,000USD27,219,000USD15,801,000USD5,595,000USD-1,364,000USD
    Tax Provision—381,000USD647,000USD2,347,000USD-225,000USD-166,000USD-1,143,000USD3,610,000USD
    Net Income From Continuing Ops—-615,000USD20,073,000USD11,159,000USD27,219,000USD15,561,000USD5,273,000USD-1,364,000USD
    Ebit—-234,000USD20,720,000USD13,506,000USD26,994,000USD15,635,000USD4,452,000USD2,246,000USD
    Ebitda—2,372,000USD24,284,000USD16,867,000USD30,690,000USD19,552,000USD9,039,000USD4,901,000USD
    Depreciation And Amortization—2,606,000USD3,564,000USD3,361,000USD3,696,000USD3,917,000USD4,587,000USD2,655,000USD
    Reconciled Depreciation—2,512,000USD3,564,000USD3,363,000USD3,696,000USD3,734,000USD4,025,000USD2,897,000USD
    Interest Expense——2,673,000USD—2,673,000USD1,961,000USD3,304,000USD448,000USD
    Non Operating Income Net Other————2,673,000USD1,961,000USD3,255,000USD448,000USD
    Net Income Applicable To Common Shares————27,219,000USD15,562,000USD5,273,000USD-1,364,000USD
    Source0001116463-26-000052DeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20232023-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USDFY 20172017-12-31 · USDFY 20162016-12-31 · USDFY 20152015-12-31 · USD
    Total Revenue405,472,000USD154,605,000USD181,743,000USD167,064,000USD128,198,000USD119,719,000USD
    Cost Of Revenue226,051,000USD60,022,000USD68,130,000USD68,108,000USD40,171,000USD39,426,000USD
    Gross Profit179,421,000USD94,583,000USD113,613,000USD98,956,000USD88,027,000USD80,293,000USD
    Research Development33,162,000USD19,629,000USD16,250,000USD13,365,000USD9,754,000USD11,654,000USD
    Selling General Administrative57,404,000USD35,287,000USD38,325,000USD29,321,000USD28,356,000USD25,493,000USD
    Selling And Marketing Expenses34,776,000USD——28,532,000USD29,652,000USD35,088,000USD
    Total Operating Expenses125,342,000USD85,587,000USD74,347,000USD71,218,000USD67,762,000USD72,235,000USD
    Operating Income54,079,000USD8,996,000USD39,266,000USD27,738,000USD20,265,000USD8,058,000USD
    Income Before Tax56,258,000USD21,331,000USD31,716,000USD41,032,000USD20,323,000USD8,832,000USD
    Income Tax Expense2,603,000USD4,675,000USD11,320,000USD10,084,000USD603,000USD665,000USD
    Tax Provision1,790,000USD4,675,000USD11,320,000USD10,084,000USD603,000USD665,000USD
    Net Income53,655,000USD16,655,999USD20,396,000USD30,948,000USD19,720,000USD8,167,000USD
    Net Income From Continuing Ops48,582,000USD16,656,000USD20,396,000USD30,948,000USD19,720,000USD8,167,000USD
    Ebit56,258,000USD8,996,000USD39,266,000USD27,738,000USD20,265,000USD8,058,000USD
    Ebitda76,158,000USD16,335,000USD45,717,000USD34,140,000USD25,952,000USD13,754,000USD
    Depreciation And Amortization19,900,000USD7,339,000USD6,451,000USD6,402,000USD5,687,000USD5,696,000USD
    Reconciled Depreciation21,109,000USD7,730,000USD7,222,000USD6,402,000USD——
    Total Other Income Expense Net2,179,000USD12,335,000USD-7,550,000USD13,294,000USD58,000USD774,000USD
    Unclassified Operating Expenses—30,671,000USD19,772,000USD———
    Interest Income—1,339,000USD831,000USD———
    Interest Expense—24,346,000USD3,287,000USD794,000USD58,000USD774,000USD
    Net Income Applicable To Common Shares—16,656,000USD20,396,000USD30,948,000USD19,720,000USD8,167,000USD
    Non Operating Income Net Other——3,287,000USD794,000USD58,000USD774,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets360,552,000USD379,169,000USD403,168,000USD423,098,000USD445,035,000USD457,607,000USD479,659,000USD464,085,000USD
    Cash And Equivalents160,582,000USD———————
    Total Current Assets222,937,000USD240,781,000USD261,908,000USD283,011,000USD301,438,000USD313,781,000USD333,220,000USD350,151,000USD
    Other Current Assets1,554,000USD7,095,000USD9,367,000USD8,832,000USD7,585,000USD9,019,000USD7,444,000USD5,756,000USD
    Other Non Current Assets1,410,000USD———————
    Total Liabilities42,775,000USD———————
    Total Current Liabilities25,119,000USD44,084,000USD39,795,000USD40,248,000USD42,350,000USD25,422,000USD33,483,000USD27,784,000USD
    Other Non Current Liabilities2,478,000USD———————
    Total Stockholder Equity317,777,000USD313,324,000USD340,827,000USD361,980,000USD380,721,000USD396,282,000USD410,338,000USD425,565,000USD
    Total Equity Including Noncontrolling Interest317,777,000USD———————
    Deferred Revenue851,000USD———————
    Net Receivables25,597,000USD26,415,000USD22,203,000USD24,300,000USD25,900,000USD21,516,000USD23,816,000USD26,954,000USD
    Inventory30,071,000USD30,307,000USD31,060,000USD33,401,000USD33,375,000USD35,677,000USD34,197,000USD38,870,000USD
    Property Plant Equipment Net49,667,000USD49,608,000USD51,321,000USD53,199,000USD55,039,000USD56,294,000USD58,692,000USD48,204,000USD
    Goodwill42,717,000USD———————
    Intangible Assets18,835,000USD18,940,000USD19,046,000USD17,202,000USD17,266,000USD17,307,000USD17,435,000USD665,000USD
    Accounts Payable8,401,000USD10,628,000USD6,521,000USD6,360,000USD6,380,000USD7,820,000USD8,173,000USD9,581,000USD
    Short Term Debt2,065,000USD20,994,000USD2,227,000USD2,108,000USD2,148,000USD2,132,000USD2,170,000USD1,571,000USD
    Common Stock0USD———————
    Retained Earnings-188,290,000USD-194,539,000USD-172,162,000USD-152,876,000USD-139,164,000USD-119,471,000USD-103,431,000USD-92,637,000USD
    Accumulated Other Comprehensive Income-21,897,000USD-20,037,000USD-18,404,000USD-20,173,000USD-17,371,000USD-24,122,000USD-24,360,000USD-17,200,000USD
    Total Liab—65,845,000USD62,341,000USD61,118,000USD64,314,000USD61,325,000USD69,321,000USD38,520,000USD
    Other Current Liab—11,590,000USD29,529,000USD29,901,000USD30,287,000USD11,912,000USD18,840,000USD13,785,000USD
    Capital Stock—0USD0USD0USD0USD0USD0USD0USD
    Good Will—43,047,000USD43,363,000USD41,313,000USD41,745,000USD40,449,000USD40,330,000USD35,287,000USD
    Other Assets—47,247USD49,039USD—50,016USD—1USD—
    Cash—176,964,000USD199,278,000USD216,478,000USD234,578,000USD247,569,000USD267,763,000USD278,571,000USD
    Cash And Short Term Investments—176,964,000USD199,278,000USD216,478,000USD234,578,000USD247,569,000USD267,763,000USD278,571,000USD
    Current Deferred Revenue—872,000USD1,518,000USD1,879,000USD2,446,000USD2,510,000USD2,961,000USD1,619,000USD
    Net Debt—-136,499,000USD-186,081,000USD-203,013,000USD-220,453,000USD-233,367,000USD-253,159,000USD-267,464,000USD
    Short Long Term Debt Total—40,465,000USD13,197,000USD13,465,000USD14,125,000USD14,202,000USD14,604,000USD11,107,000USD
    Long Term Investments—24,868,000USD25,956,000USD26,600,000USD26,974,000USD27,776,000USD28,300,000USD28,829,000USD
    Property Plant Equipment Gross—114,547,000USD114,197,000USD126,317,000USD126,139,000USD124,321,000USD124,610,000USD127,766,000USD
    Common Stock Shares Outstanding—69,675,000shares71,566,000shares73,004,000shares74,541,000shares74,867,000shares74,434,000shares74,583,000shares
    Non Current Assets Total—138,387,999USD141,260,000USD140,087,000USD143,597,000USD143,826,000USD146,439,000USD113,934,000USD
    Non Current Liabilities Total—21,760,999USD22,546,000USD20,870,000USD21,964,000USD35,903,000USD35,838,000USD10,736,000USD
    Non Current Liabilities Other—11,319,000USD11,576,000USD9,513,000USD9,987,000USD23,833,000USD23,404,000USD529,000USD
    Non Currrent Assets Other—1,281,999USD1,303,000USD1,562,000USD2,573,000USD1,460,000USD1,526,000USD278,000USD
    Net Working Capital—196,697,000USD222,113,000USD242,763,000USD259,088,000USD288,359,000USD299,737,000USD322,367,000USD
    Unclassified Non Current Liabilities—10,441,999USD10,970,000USD11,357,000USD11,977,000USD12,070,000USD12,434,000USD10,207,000USD
    Unclassified Equity—527,900,000USD531,393,000USD535,029,000USD537,256,000USD539,875,000USD538,129,000USD535,402,000USD
    Unclassified Current Liabilities————1,089,000USD1,048,000USD1,339,000USD1,228,000USD
    Short Term Investments——————-1USD—
    Source0001116463-26-000052DeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets403,168,000USD479,659,000USD482,845,000USD444,180,000USD460,990,000USD454,472,000USD349,295,000USD315,571,000USD
    Intangible Assets19,046,000USD17,435,000USD1,206,000USD11,694,000USD14,343,000USD17,904,000USD14,674,000USD5,137,000USD
    Other Current Assets9,367,000USD7,444,000USD8,267,000USD47,842,000USD47,804,000USD8,794,000USD8,109,000USD5,010,000USD
    Total Liab62,341,000USD69,321,000USD52,174,000USD79,755,000USD80,457,000USD55,901,000USD42,150,000USD32,193,000USD
    Total Stockholder Equity340,827,000USD410,338,000USD430,671,000USD364,425,000USD380,533,000USD398,571,000USD307,145,000USD283,378,000USD
    Other Current Liab29,529,000USD18,840,000USD21,465,000USD24,308,000USD31,757,000USD20,229,000USD17,788,000USD12,414,000USD
    Capital Stock0USD0USD0USD0USD0USD0USD0USD0USD
    Retained Earnings-172,162,000USD-103,431,000USD-83,931,000USD-137,586,000USD-120,453,000USD-97,455,000USD-82,533,000USD-99,189,000USD
    Good Will43,363,000USD40,330,000USD35,696,000USD35,104,000USD40,279,000USD40,351,000USD36,201,000USD18,521,000USD
    Other Assets49,039USD——60,621USD50,448USD7,746,000USD3,164,000USD3,550,000USD
    Cash199,278,000USD267,763,000USD290,407,000USD83,980,000USD116,762,000USD160,802,000USD75,715,000USD88,438,000USD
    Cash And Short Term Investments199,278,000USD267,763,000USD290,407,000USD110,847,000USD153,041,000USD209,401,000USD156,338,000USD156,572,000USD
    Total Current Assets261,908,000USD333,220,000USD386,459,000USD325,190,000USD299,306,000USD288,893,000USD224,550,000USD219,312,000USD
    Total Current Liabilities39,795,000USD33,483,000USD39,536,000USD69,063,000USD68,064,000USD46,489,000USD32,713,000USD27,980,000USD
    Current Deferred Revenue1,518,000USD2,961,000USD1,559,000USD2,273,000USD2,936,000USD4,811,000USD3,713,000USD3,521,000USD
    Net Debt-186,081,000USD-253,159,000USD-276,903,000USD-71,433,000USD-104,488,000USD-154,674,000USD-68,492,000USD-88,438,000USD
    Short Term Debt2,227,000USD2,170,000USD2,116,000USD2,943,000USD3,120,000USD1,642,000USD1,645,000USD—
    Short Long Term Debt Total13,197,000USD14,604,000USD13,504,000USD12,547,000USD12,274,000USD6,128,000USD7,223,000USD—
    Long Term Investments25,956,000USD28,300,000USD0USD0USD17,009,000USD47,718,000USD33,420,000USD44,752,000USD
    Net Receivables22,203,000USD23,816,000USD40,171,000USD70,797,000USD45,323,000USD38,835,000USD36,948,000USD34,842,000USD
    Inventory31,060,000USD34,197,000USD47,614,000USD95,704,000USD53,138,000USD31,863,000USD23,155,000USD22,888,000USD
    Accounts Payable6,521,000USD8,173,000USD13,151,000USD38,020,000USD28,024,000USD17,407,000USD9,567,000USD10,598,000USD
    Property Plant Equipment Net51,321,000USD58,692,000USD58,266,000USD71,105,000USD84,984,000USD57,633,000USD37,286,000USD24,299,000USD
    Property Plant Equipment Gross114,197,000USD124,610,000USD143,409,000USD140,986,000USD160,870,000USD57,633,000USD37,286,000USD24,299,000USD
    Accumulated Other Comprehensive Income-18,404,000USD-24,360,000USD-14,941,000USD-18,435,000USD-10,077,000USD-9,097,000USD-12,136,000USD-18,706,000USD
    Common Stock Shares Outstanding73,485,000shares74,434,000shares74,389,000shares72,505,000shares71,981,000shares67,505,000shares62,170,000shares62,532,000shares
    Non Current Assets Total141,260,000USD146,439,000USD96,386,000USD118,990,000USD161,684,000USD165,579,000USD124,745,000USD96,259,000USD
    Non Current Liabilities Total22,546,000USD35,838,000USD12,638,000USD10,692,000USD12,393,000USD9,412,000USD9,437,000USD4,213,000USD
    Non Current Liabilities Other11,576,000USD23,404,000USD696,000USD10,692,000USD12,393,000USD8,217,000USD2,960,000USD3,312,000USD
    Non Currrent Assets Other1,303,000USD1,526,000USD1,218,000USD1,087,000USD5,069,000USD1,973,000USD3,164,000USD3,550,000USD
    Net Working Capital222,113,000USD299,737,000USD346,923,000USD255,326,000USD220,367,000USD242,404,000USD191,837,000USD191,332,000USD
    Unclassified Non Current Liabilities10,970,000USD12,434,000USD11,942,000USD-1,496,000USD-14,627,000USD-4,926,000USD2,618,000USD-4,213,000USD
    Unclassified Equity531,393,000USD538,129,000USD529,543,000USD520,446,000USD130,530,000USD505,123,000USD94,669,000USD117,895,000USD
    Unclassified Current Liabilities—1,339,000USD1,245,000USD1,519,000USD2,227,000USD2,400,000USD—1,447,000USD
    Short Term Investments——0USD26,867,000USD36,279,000USD48,599,000USD80,623,000USD68,134,000USD
    Deferred Long Term Liab———408,000USD2,234,000USD1,195,000USD—901,000USD
    Other Liab———1,088,000USD12,393,000USD4,926,000USD3,859,000USD4,213,000USD
    Net Tangible Assets———316,826,000USD325,911,000USD340,316,000USD256,270,000USD259,720,000USD
    Common Stock————380,533,000USD—307,145,000USD283,378,000USD
    Unclassified Non Current Assets—————-7,746,000USD-3,164,000USD-3,550,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation4,712,000USD
    Stock Based Compensation5,055,000USD
    Deferred Income Tax-152,000USD
    Change To Account Receivables-3,710,000USD
    Change To Inventory890,000USD
    Change To Liabilities4,194,000USD
    Change In Working Capital972,000USD
    Operating Cash Flow-23,816,000USD
    Capital Expenditures-3,341,000USD
    Other Investing Activities20,000USD
    Investing Cash Flow-3,321,000USD
    Net Debt Issuance-45,000USD
    Net Common Stock Issuance-8,484,000USD
    Financing Cash Flow-8,529,000USD
    Effect Of Forex Changes On Cash-3,030,000USD
    Change In Cash-38,696,000USD
    End Cash Flow160,582,000USD
    Source0001116463-26-000052DeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-22,377,000USD-16,043,246USD-13,712,000USD-19,693,000USD-16,040,000USD-10,794,000USD-4,507,000USD-615,000USD
    Depreciation2,259,000USD2,807,595USD2,381,000USD2,416,000USD2,808,000USD2,492,000USD3,049,000USD2,512,000USD
    Stock Based Compensation2,768,000USD2,685,773USD2,835,000USD3,165,000USD2,687,000USD2,742,000USD2,888,000USD3,322,000USD
    Other Non Cash Items1,097,000USD-428,489USD483,000USD1,765,000USD133,000USD661,000USD282,000USD1,925,000USD
    Change To Account Receivables-2,621,000USD1,965,000USD1,547,000USD-3,976,000USD2,413,000USD3,214,000USD10,856,000USD-4,397,000USD
    Change To Inventory714,000USD2,668,000USD-115,000USD2,491,000USD-1,482,000USD4,437,000USD-561,000USD4,883,000USD
    Change In Working Capital2,712,000USD2,366,000USD-2,792,000USD2,560,000USD-8,937,000USD5,830,000USD10,896,000USD662,000USD
    Total Cash From Operating Activities-13,895,000USD-8,996,000USD-10,071,000USD-10,223,000USD-19,733,000USD109,000USD12,682,000USD7,844,000USD
    Capital Expenditures-913,000USD-922,000USD-919,000USD-1,936,000USD-420,000USD-456,000USD-145,000USD-1,617,000USD
    Free Cash Flow-14,808,000USD-9,918,000USD-10,990,000USD-12,159,000USD-20,153,000USD-347,000USD12,537,000USD6,227,000USD
    Total Cashflows From Investing Activities-913,000USD-4,423,000USD-821,000USD-1,936,000USD370,000USD-5,493,000USD7,332,000USD5,663,000USD
    Net Borrowings-21,000USD-18,000USD-17,000USD-14,000USD-12,000USD-96,000USD-639,000USD—
    Total Cash From Financing Activities-6,282,000USD-5,114,000USD-5,079,000USD-5,798,000USD-953,000USD-111,000USD-727,000USD-2,041,000USD
    Sale Purchase Of Stock-5,000,000USD-5,039,000USD-5,001,000USD-4,059,000USD-941,000USD-15,000USD-87,000USD1,462,000USD
    Change In Cash-22,314,000USD-17,200,000USD-18,100,000USD-12,991,000USD-20,194,000USD-10,808,000USD20,332,000USD11,094,000USD
    Begin Period Cash Flow199,278,000USD216,478,000USD234,578,000USD247,569,000USD267,763,000USD278,571,000USD258,239,000USD247,145,000USD
    End Period Cash Flow176,964,000USD199,278,000USD216,478,000USD234,578,000USD247,569,000USD267,763,000USD278,571,000USD258,239,000USD
    Other Cashflows From Financing Activities-1,261,000USD-57,000USD-61,000USD-1,725,000USD-953,000USD-96,000USD-1,000USD-3,446,000USD
    Investments—0USD-821,000USD-1,936,000USD370,000USD-5,493,000USD7,332,000USD5,663,000USD
    Other Cashflows From Investing Activities—-3,998,885USD98,000USD-2,353,644USD790,000USD—-58,333,000USD7,280,000USD
    Unclassified Investing Cash Flow———4,289,644USD——58,478,000USD-5,663,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income-68,731USD-19,500,000USD53,655,000USD-17,934,000USD-22,998,000USD-14,922,000USD16,656,000USD20,396,000USD
    Depreciation10,192USD10,872,000USD20,939,000USD15,536,000USD12,495,000USD9,714,000USD7,730,000USD7,222,000USD
    Stock Based Compensation10,147USD11,920,000USD10,729,000USD11,622,000USD7,807,000USD7,139,000USD4,057,000USD15,237,000USD
    Other Non Cash Items6,802,472USD5,921,000USD10,403,000USD15,789,000USD4,723,000USD-424,000USD-8,277,000USD-400,000USD
    Change To Account Receivables1,949,000USD15,872,000USD31,116,000USD-25,162,000USD-6,451,000USD-2,324,000USD-2,210,000USD6,635,000USD
    Change To Inventory3,562,000USD13,096,000USD48,228,000USD-43,048,000USD-27,941,000USD-8,607,000USD-1,044,000USD-3,857,000USD
    Change In Working Capital-6,803,000USD18,818,000USD45,755,000USD-70,564,000USD-38,435,000USD4,692,000USD-8,905,000USD-2,446,000USD
    Total Cash From Operating Activities-49,023USD27,374,000USD141,583,000USD-47,202,000USD-35,382,000USD5,807,000USD9,804,000USD39,090,000USD
    Capital Expenditures-4,197USD-3,797,000USD-10,303,000USD-63,909,000USD-48,117,000USD-28,924,000USD-9,314,000USD-6,344,000USD
    Free Cash Flow-53,220USD23,577,000USD131,280,000USD-111,111,000USD-83,499,000USD-23,117,000USD490,000USD32,746,000USD
    Investments0USD-39,026,000USD61,173,000USD24,542,000USD42,103,000USD17,581,000USD-19,797,000USD-11,083,000USD
    Total Cashflows From Investing Activities-6,810USD-39,026,000USD66,154,000USD21,085,000USD-5,501,000USD-14,029,000USD-19,797,000USD-17,427,000USD
    Net Borrowings-61,000USD-842,000USD-1,345,000USD-1,381,000USD-686,000USD-687,000USD-1,166,000USD-1,166,000USD
    Total Cash From Financing Activities-16,944USD-4,176,000USD-3,023,000USD-3,828,000USD-2,817,000USD92,479,000USD-4,682,000USD-1,891,000USD
    Sale Purchase Of Stock-15,040,000USD-3,548,000USD-1,901,000USD-2,254,000USD-2,113,000USD-2,088,000USD-3,712,000USD-3,592,000USD
    Change In Cash-68,485USD-22,644,000USD206,427,000USD-32,782,000USD-44,040,000USD85,087,000USD-12,723,000USD15,569,000USD
    Begin Period Cash Flow267,763USD290,407,000USD83,980,000USD116,762,000USD160,802,000USD75,715,000USD88,438,000USD72,869,000USD
    End Period Cash Flow199,278USD267,763,000USD290,407,000USD83,980,000USD116,762,000USD160,802,000USD75,715,000USD88,438,000USD
    Other Cashflows From Investing Activities1,000USD-30,000,000USD48,669,000USD60,331,000USD513,000USD-4,936,000USD13,318,000USD-11,083,000USD
    Other Cashflows From Financing Activities15,084,056USD214,000USD223,000USD-193,000USD-18,000USD3,440,000USD196,000USD1,701,000USD
    Unclassified Investing Cash Flow—33,797,000USD-33,385,000USD——2,250,000USD-4,004,000USD11,083,000USD
    Dividends Paid——-1,345,000USD—-246,000USD-3,222,000USD-196,000USD—
    Unclassified Financing Cash Flow——1,345,000USD——95,036,000USD—1,166,000USD
    Change To Liabilities———5,333,000USD6,522,000USD14,676,000USD-1,834,000USD-7,098,000USD
    Issuance Of Capital Stock———0USD0USD95,036,000USD——
    Cash And Cash Equivalents Changes———-29,945,000USD-43,700,000USD84,257,000USD—19,772,000USD
    Unclassified Operating Cash Flow———-1,651,000USD1,026,000USD—-1,457,000USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q1 2026Quarterly · 2026-03-31GeographyAfrica6,774,000USD0001116463-26-000041
    Q1 2026Quarterly · 2026-03-31GeographyEurope1,449,000USD0001116463-26-000041
    Q1 2026Quarterly · 2026-03-31GeographyOther Foreign Countries1,030,000USD0001116463-26-000041
    Q1 2026Quarterly · 2026-03-31GeographyUnited States18,672,000USD0001116463-26-000041
    Q1 2026Quarterly · 2026-03-31ProductOther Product And Services Revenues3,167,000USD0001116463-26-000041
    Q1 2026Quarterly · 2026-03-31ProductProduct And Services — COVID1918,000USD0001116463-26-000041
    Q1 2026Quarterly · 2026-03-31ProductProduct And Services — Hcv2,663,000USD0001116463-26-000041
    Q1 2026Quarterly · 2026-03-31ProductProduct And Services — Hiv13,019,000USD0001116463-26-000041
    Q1 2026Quarterly · 2026-03-31ProductProduct And Services — Molecular Products9,058,000USD0001116463-26-000041
    Q1 2026Quarterly · 2026-03-31ProductRisk Assessment Testing0USD0001116463-26-000041
    Q4 2025Quarterly · 2025-12-31GeographyAfrica3,902,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31GeographyEurope2,339,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31GeographyOther Foreign Countries2,119,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31GeographyUnited States18,403,000USDLegacy provider
    FY 2025Yearly · 2025-12-31GeographyAfrica23,993,000USD0001116463-26-000016
    FY 2025Yearly · 2025-12-31GeographyEurope7,393,000USD0001116463-26-000016
    FY 2025Yearly · 2025-12-31GeographyOther Foreign Countries5,383,000USD0001116463-26-000016
    FY 2025Yearly · 2025-12-31GeographyUnited States78,252,000USD0001116463-26-000016
    FY 2025Yearly · 2025-12-31ProductMolecular Services0USD0001116463-26-000016
    FY 2025Yearly · 2025-12-31ProductOther Product And Services Revenues6,590,000USD0001116463-26-000016
    FY 2025Yearly · 2025-12-31ProductProduct And Services — COVID1913,759,000USD0001116463-26-000016
    FY 2025Yearly · 2025-12-31ProductProduct And Services — Hcv4,648,000USD0001116463-26-000016
    FY 2025Yearly · 2025-12-31ProductProduct And Services — Hiv49,802,000USD0001116463-26-000016
    FY 2025Yearly · 2025-12-31ProductProduct And Services — Molecular Products38,356,000USD0001116463-26-000016
    FY 2025Yearly · 2025-12-31ProductProduct And Services — Risk Assessment Testing1,866,000USD0001116463-26-000016
    Q3 2025Quarterly · 2025-09-30GeographyAfrica4,875,000USD0001116463-25-000054
    Q3 2025Quarterly · 2025-09-30GeographyEurope1,300,000USD0001116463-25-000054
    Q3 2025Quarterly · 2025-09-30GeographyOther Foreign Countries1,248,000USD0001116463-25-000054
    Q3 2025Quarterly · 2025-09-30GeographyUnited States19,662,000USD0001116463-25-000054
    Q3 2025Quarterly · 2025-09-30ProductMolecular Services0USD0001116463-25-000054
    Q3 2025Quarterly · 2025-09-30ProductOther Product And Services Revenues2,945,000USD0001116463-25-000054
    Q3 2025Quarterly · 2025-09-30ProductProduct And Services — COVID1989,000USD0001116463-25-000054
    Q3 2025Quarterly · 2025-09-30ProductProduct And Services — Hcv2,604,000USD0001116463-25-000054
    Q3 2025Quarterly · 2025-09-30ProductProduct And Services — Hiv11,141,000USD0001116463-25-000054
    Q3 2025Quarterly · 2025-09-30ProductProduct And Services — Molecular Products10,306,000USD0001116463-25-000054
    Q3 2025Quarterly · 2025-09-30ProductRisk Assessment Testing0USD0001116463-25-000054
    Q2 2025Quarterly · 2025-06-30GeographyAfrica8,027,000USD0001628280-25-038379
    Q2 2025Quarterly · 2025-06-30GeographyEurope2,117,000USD0001628280-25-038379
    Q2 2025Quarterly · 2025-06-30GeographyOther Foreign Countries1,246,000USD0001628280-25-038379
    Q2 2025Quarterly · 2025-06-30GeographyUnited States19,852,000USD0001628280-25-038379
    Q2 2025Quarterly · 2025-06-30ProductMolecular Services0USD0001628280-25-038379
    Q2 2025Quarterly · 2025-06-30ProductOther Product And Services Revenues2,389,000USD0001628280-25-038379
    Q2 2025Quarterly · 2025-06-30ProductProduct And Services — COVID1928,000USD0001628280-25-038379
    Q2 2025Quarterly · 2025-06-30ProductProduct And Services — Hcv4,126,000USD0001628280-25-038379
    Q2 2025Quarterly · 2025-06-30ProductProduct And Services — Hiv14,398,000USD0001628280-25-038379
    Q2 2025Quarterly · 2025-06-30ProductProduct And Services — Molecular Products9,855,000USD0001628280-25-038379
    Q2 2025Quarterly · 2025-06-30ProductProduct And Services — Risk Assessment Testing446,000USD0001628280-25-038379
    Q1 2025Quarterly · 2025-03-31GeographyAfrica7,189,000USD0001116463-26-000041
    Q1 2025Quarterly · 2025-03-31GeographyEurope1,637,000USD0001116463-26-000041
    Q1 2025Quarterly · 2025-03-31GeographyOther Foreign Countries770,000USD0001116463-26-000041
    Q1 2025Quarterly · 2025-03-31GeographyUnited States20,335,000USD0001116463-26-000041
    Q1 2025Quarterly · 2025-03-31ProductMolecular Services0USD0001116463-25-000038
    Q1 2025Quarterly · 2025-03-31ProductOther Product And Services Revenues1,707,000USD0001116463-25-000038
    Q1 2025Quarterly · 2025-03-31ProductProduct And Services — COVID19461,000USD0001116463-25-000038
    Q1 2025Quarterly · 2025-03-31ProductProduct And Services — Hcv4,333,000USD0001116463-25-000038
    Q1 2025Quarterly · 2025-03-31ProductProduct And Services — Hiv12,900,000USD0001116463-25-000038
    Q1 2025Quarterly · 2025-03-31ProductProduct And Services — Molecular Products9,110,000USD0001116463-25-000038
    Q1 2025Quarterly · 2025-03-31ProductProduct And Services — Risk Assessment Testing1,420,000USD0001116463-25-000038
    Q4 2024Quarterly · 2024-12-31GeographyAfrica9,299,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31GeographyEurope2,532,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31GeographyOther Foreign Countries1,403,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31GeographyUnited States24,211,000USDLegacy provider
    FY 2024Yearly · 2024-12-31GeographyAfrica32,745,000USD0001116463-26-000016
    FY 2024Yearly · 2024-12-31GeographyEurope8,424,000USD0001116463-26-000016
    FY 2024Yearly · 2024-12-31GeographyOther Foreign Countries5,497,000USD0001116463-26-000016
    FY 2024Yearly · 2024-12-31GeographyUnited States139,161,000USD0001116463-26-000016
    FY 2024Yearly · 2024-12-31ProductMolecular Services1,705,000USD0001116463-25-000010
    FY 2024Yearly · 2024-12-31ProductOther Non Product Revenues1,216,000USD0001116463-25-000010
    FY 2024Yearly · 2024-12-31ProductOther Product And Services Revenues3,506,000USD0001116463-25-000010
    FY 2024Yearly · 2024-12-31ProductOther Revenues1,216,000USD0001116463-25-000010
    FY 2024Yearly · 2024-12-31ProductProduct And Services — COVID1945,172,000USD0001116463-25-000010
    FY 2024Yearly · 2024-12-31ProductProduct And Services — Hcv14,024,000USD0001116463-25-000010
    FY 2024Yearly · 2024-12-31ProductProduct And Services — Hiv60,804,000USD0001116463-25-000010
    FY 2024Yearly · 2024-12-31ProductProduct And Services — Molecular Products51,046,000USD0001116463-25-000010
    FY 2024Yearly · 2024-12-31ProductProduct And Services — Risk Assessment Testing8,354,000USD0001116463-25-000010
    Q3 2024Quarterly · 2024-09-30GeographyAfrica11,376,000USD0001116463-25-000054
    Q3 2024Quarterly · 2024-09-30GeographyEurope2,126,000USD0001116463-25-000054
    Q3 2024Quarterly · 2024-09-30GeographyOther Foreign Countries1,060,000USD0001116463-25-000054
    Q3 2024Quarterly · 2024-09-30GeographyUnited States25,353,000USD0001116463-25-000054
    Q3 2024Quarterly · 2024-09-30ProductGovernment Contract0USD0001116463-24-000049
    Q3 2024Quarterly · 2024-09-30ProductMolecular Services9,000USD0001116463-24-000049
    Q3 2024Quarterly · 2024-09-30ProductOther Non Product Revenues263,000USD0001116463-24-000049
    Q3 2024Quarterly · 2024-09-30ProductOther Product And Services Revenues1,196,000USD0001116463-24-000049
    Q3 2024Quarterly · 2024-09-30ProductOther Revenues264,000USD0001116463-24-000049
    Q3 2024Quarterly · 2024-09-30ProductProduct And Services — COVID192,155,000USD0001116463-24-000049
    Q3 2024Quarterly · 2024-09-30ProductProduct And Services — Hcv3,228,000USD0001116463-24-000049
    Q3 2024Quarterly · 2024-09-30ProductProduct And Services — Hiv18,347,000USD0001116463-24-000049
    Q3 2024Quarterly · 2024-09-30ProductProduct And Services — Molecular Sample Management Solutions12,806,000USD0001116463-24-000049
    Q3 2024Quarterly · 2024-09-30ProductProduct And Services — Risk Assessment Testing1,911,000USD0001116463-24-000049
    Q2 2024Quarterly · 2024-06-30GeographyAfrica6,366,000USD0001628280-25-038379
    Q2 2024Quarterly · 2024-06-30GeographyEurope2,164,000USD0001628280-25-038379
    Q2 2024Quarterly · 2024-06-30GeographyOther Foreign Countries1,419,000USD0001628280-25-038379
    Q2 2024Quarterly · 2024-06-30GeographyUnited States44,386,000USD0001628280-25-038379
    Q2 2024Quarterly · 2024-06-30ProductMolecular Services897,000USD0001628280-25-038379
    Q2 2024Quarterly · 2024-06-30ProductOther Non Product Revenues386,000USD0001628280-25-038379
    Q2 2024Quarterly · 2024-06-30ProductOther Product And Services Revenues2,308,000USD0001628280-25-038379
    Q2 2024Quarterly · 2024-06-30ProductOther Revenues386,000USD0001628280-25-038379
    Q2 2024Quarterly · 2024-06-30ProductProduct And Services — COVID19810,000USD0001628280-25-038379
    Q2 2024Quarterly · 2024-06-30ProductProduct And Services — Hcv12,609,000USD0001628280-25-038379
    Q2 2024Quarterly · 2024-06-30ProductProduct And Services — Hiv18,939,000USD0001628280-25-038379

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.